Cell2Sell: commercial scale next generation platform for allogeneic stem cell production

This project will develop a next generation industrialised cGMP platform for the production of ReNeuron's allogeneic stem cell products which target significant, growing areas of unmet clinical need. The recent Advanced Therapy Medicinal Products Taskforce of the Medicines Manufacturing Industrial Partnership has identified that the ATMP industry is at a critical stage with the focus now on manufacturing industrialisation in order to commercialise these therapies further strengthening the UKs position as a global hub for researching, developing, manufacturing and adopting regenerative medicine. Developing the UK as a major progressive global hub for the ATMP sector will leverage further investments. This project involves organisations in Great Britain and will result in an at scale, validatable, cGMP manufacturing process for clinical and commercial supply. It will create and secure jobs in the UK, accelerate the development of skills and capabilities for individuals and organisations. ReN's products are currently in clinical trials in Stroke, Critical Limb Ischemia and Retinitis Pigmentosa, and therefore have the potential to significantly improve quality of life for large numbers of patients in areas of unmet clinical need, reducing the costs of social care therefore saving money in the economy.